Developer docs
API playgroundTry for free, no card

Search company profiles

Sea Pharmaceuticals

Full company profile

uuid0003kiz

Namestring
Sea Pharmaceuticals
Legal namestring
Sea Pharmaceuticals, LLC
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Sea Pharmaceuticals, LLC is a privately held, pre-clinical stage biopharmaceutical company founded in 2013 by J.P. Pearson (President, CEO, CSO) and E.J. Martinez (VP Chemistry, co-founder), operating from Cambridge, Massachusetts with 11-50 employees. The company develops proprietary oral synthetic small molecule neurotherapeutics for high-need central nervous system (CNS) disorders, targeting constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) indications that collectively address millions of underserved U.S. patients.

The company's core technology platform consists of dual AMPAR/KAINR antagonists (DAKAs), synthetic small molecules designed to selectively inhibit both AMPA and kainate glutamate receptors and thereby dampen excitatory glutamate neurotransmission in the CNS. Lead candidate SPM-0404 is in IND-enabling studies and demonstrates CNS penetration with acceptable pharmacokinetics in rats and non-human primates, anti-seizure efficacy in mouse 6-Hz and rat MES seizure models, and in vitro activity confirmed via whole cell patch-clamp electrophysiology using rat neurons and human HEK293 recombinant cells. A second-generation candidate, SPM-0606, extends the portfolio. The DAKA chemistry is protected by a 100% Sea-owned patent estate covering composition of matter for both compounds, with selective dual-receptor antagonism positioned as a differentiated approach versus prior single-target AMPAR or KAINR antagonists.

As a pre-clinical R&D company with no FDA-approved or commercialized products, Sea Pharmaceuticals generates no revenue and operates a capital-funded, partnership-driven business model. Strategic collaborations with TCG GreenChem, Inc. (November 2024) for cGMP process development and with Inotiv, Inc. (April 2025) for IND-enabling pre-clinical studies outsource the operational execution required to advance SPM-0404 toward regulatory filing. Capital is sourced from securities offerings registered via SEC exemptions (approximately $1.49M sold of a $2M filing, plus an additional $417K raised in February 2025), with proceeds allocated primarily to personnel compensation. Marketing and distribution channels remain undeveloped, with go-to-market economics contingent on future FDA approval and subsequent commercialization through specialty pharmacy and HCP channels for prescription CNS therapeutics.

Short descriptiontext

Sea Pharmaceuticals is a privately held pre-clinical biopharmaceutical company developing proprietary oral dual AMPAR/KAINR antagonist (DAKA) small molecules targeting tinnitus, epilepsy, and sporadic ALS, with lead candidate SPM-0404 in IND-enabling studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug development, neurotherapeutics research, small molecule therapeutics, tinnitus treatment development, epilepsy drug development
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Neurotherapeutics R&D
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sea Pharmaceuticals is a private pre-clinical stage therapeutics R&D company developing proprietary synthetic small molecule drug candidates known as Dual AMPAR/KAINR Antagonists (DAKAs). Lead molecule SPM-0404 and second-generation SPM-0606 are being advanced through IND-enabling studies as potential oral treatments for constant bothersome tinnitus, epilepsy, and sporadic ALS. The molecules dampen excitatory glutamate neurotransmission in the CNS and demonstrate CNS penetration with acceptable pharmacokinetics in multiple species.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sea Pharmaceuticals is a private pre-clinical stage therapeutics R&D company developing a portfolio of proprietary synthetic small molecule neurotherapeutics targeting the glutamate pathway. The company's core pipeline consists of two drug candidates: lead molecule SPM-0404 and second-generation molecule SPM-0606, both functioning as dual AMPAR/KAINR antagonists (DAKAs). These oral CNS-penetrant compounds are being developed for high-need neurological disorders including tinnitus, epilepsy, and sporadic ALS. The company was founded in 2013 by J.P. Pearson and E.J. Martinez and operates from Cambridge, Massachusetts.

Product and service2 records
1SPM-0404
CategoryDrug Candidate
Description

Sea Pharmaceuticals' lead molecule SPM-0404 is a synthetic small molecule Dual AMPAR/KAINR Antagonist (DAKA) currently in IND-enabling studies. It is being developed as a potential oral treatment for constant bothersome tinnitus (CBT), epilepsy, and sporadic ALS (S-ALS). The molecule demonstrates potent and selective in vitro biological activity in whole cell patch-clamp electrophysiology recordings using rat neurons and human recombinant cells, and shows CNS penetration in rats and non-human primates with acceptable pharmacokinetics.

2SPM-0606
CategoryDrug Candidate
Description

A second-generation synthetic small molecule Dual AMPAR/KAINR Antagonist (DAKA) in Sea Pharmaceuticals' neurotherapeutic portfolio. SPM-0606 targets the glutamate neurotransmitter pathway for potential oral treatment of CNS disorders including tinnitus, epilepsy, and ALS, and is protected within Sea's 100% Sea-owned composition-of-matter patent estate.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-06
Description

Strategic relationship with Inotiv Inc. selected for pre-clinical development IND-enabling studies to support advancement of SPM-0404. Inotiv will perform development strategy, IND-enabling studies, and investigative studies. Dr. John E. Sagartz DVM PhD serves as Inotiv's Chief Strategy Officer and has collaborated with Dr. Pearson for over 20 years. Inotiv has contributed to development of many FDA-approved medicines worldwide and hundreds of IND molecules.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-14
Description

Strategic collaboration with TCG GreenChem, Inc. of Ewing NJ USA for chemical development of lead molecule SPM-0404. TCG GC will conduct process optimization and analytical method development for cGMP manufacturing of SPM-0404 for IND-enabling studies and clinical trials. Chris H. Senanayake PhD (Founder, CEO & CSO) and Joe D. Armstrong III PhD (Chief Business Officer) are synthetic organic chemists with >500 IND molecules and several FDA-approved drugs in combined >65 years in pharma industry.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS-focused clinical-stage biopharmaceutical company developing novel neurotherapeutics for epilepsy and other CNS disorders. Directly comparable as a CNS small-molecule developer targeting underserved neurological indications with high unmet need.

TypeDirect peer
Description

Clinical-stage CNS company developing therapeutics for seizure disorders, including refractory epilepsies. Comparable target indications and small-molecule CNS strategy overlapping with Sea's epilepsy program.

TypeDirect peer
Description

Clinical-stage CNS company developing precision therapies for neurological disorders including epilepsy. Similar small-molecule approach and CNS pipeline profile make it a direct comparable.

TypeDirect peer
Description

Clinical-stage CNS company focused on novel treatments for neurological diseases. Comparable as a small-cap public CNS pharma targeting underserved neurological indications with small-molecule chemistry.

5Otonomy
TypeEmerging player
Description

Clinical-stage biopharmaceutical company focused on otology, including tinnitus and hearing-related disorders. Directly comparable in the tinnitus indication where Sea is also competing.

TypeEmerging player
Description

Clinical-stage company developing regenerative therapeutics for hearing loss with tinnitus-related indications. Comparable as an emerging player addressing the same otologic/neurology patient populations.

TypeDirect peer
Description

Clinical-stage CNS biopharma with a focus on epilepsy and other neurological disorders. Comparable small-molecule CNS development strategy and indication overlap with Sea's epilepsy program.

TypeBroad incumbent
Description

Commercial-stage CNS specialty pharma with a marketed neurology/neuropsychiatry portfolio. Relevant as a larger incumbent operating in Sea's CNS specialty space and a likely partner/acquirer profile.

TypeDirect peer
Description

Clinical-stage CNS-focused biopharma developing small-molecule therapeutics across neurology and psychiatry indications. Comparable as a CNS small-molecule developer at similar pre-clinical/early clinical stage.

TypeOthers
Description

Public CRO providing pre-clinical drug development services including IND-enabling studies. Listed as a peer because Sea has selected Inotiv as its IND-enabling partner, making it both an operational collaborator and a relevant comparand for outsourced CNS pre-clinical development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sea Pharmaceuticals

Neurotherapeutics R&Dseapharmaceuticals.com

Sea Pharmaceuticals is a privately held pre-clinical biopharmaceutical company developing proprietary oral dual AMPAR/KAINR antagonist (DAKA) small molecules targeting tinnitus, epilepsy, and sporadic ALS, with lead candidate SPM-0404 in IND-enabling studies.

What Sea Pharmaceuticals does

Sea Pharmaceuticals, LLC is a privately held, pre-clinical stage biopharmaceutical company founded in 2013 by J.P. Pearson (President, CEO, CSO) and E.J. Martinez (VP Chemistry, co-founder), operating from Cambridge, Massachusetts with 11-50 employees. The company develops proprietary oral synthetic small molecule neurotherapeutics for high-need central nervous system (CNS) disorders, targeting constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) indications that collectively address millions of underserved U.S. patients.

The company's core technology platform consists of dual AMPAR/KAINR antagonists (DAKAs), synthetic small molecules designed to selectively inhibit both AMPA and kainate glutamate receptors and thereby dampen excitatory glutamate neurotransmission in the CNS. Lead candidate SPM-0404 is in IND-enabling studies and demonstrates CNS penetration with acceptable pharmacokinetics in rats and non-human primates, anti-seizure efficacy in mouse 6-Hz and rat MES seizure models, and in vitro activity confirmed via whole cell patch-clamp electrophysiology using rat neurons and human HEK293 recombinant cells. A second-generation candidate, SPM-0606, extends the portfolio. The DAKA chemistry is protected by a 100% Sea-owned patent estate covering composition of matter for both compounds, with selective dual-receptor antagonism positioned as a differentiated approach versus prior single-target AMPAR or KAINR antagonists.

As a pre-clinical R&D company with no FDA-approved or commercialized products, Sea Pharmaceuticals generates no revenue and operates a capital-funded, partnership-driven business model. Strategic collaborations with TCG GreenChem, Inc. (November 2024) for cGMP process development and with Inotiv, Inc. (April 2025) for IND-enabling pre-clinical studies outsource the operational execution required to advance SPM-0404 toward regulatory filing. Capital is sourced from securities offerings registered via SEC exemptions (approximately $1.49M sold of a $2M filing, plus an additional $417K raised in February 2025), with proceeds allocated primarily to personnel compensation. Marketing and distribution channels remain undeveloped, with go-to-market economics contingent on future FDA approval and subsequent commercialization through specialty pharmacy and HCP channels for prescription CNS therapeutics.

Sea Pharmaceuticals firmographics

Firmographics
Name
Sea Pharmaceuticals
Legal name
Sea Pharmaceuticals, LLC
Website
https://seapharmaceuticals.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Sea Pharmaceuticals is a privately held pre-clinical biopharmaceutical company developing proprietary oral dual AMPAR/KAINR antagonist (DAKA) small molecules targeting tinnitus, epilepsy, and sporadic ALS, with lead candidate SPM-0404 in IND-enabling studies.
Ownership category
akta.pro rank

Sea Pharmaceuticals industry classification

Industry
Product category
Neurotherapeutics R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • CNS drug development
  • Neurotherapeutics research
  • Small molecule therapeutics
  • Tinnitus treatment development
  • Epilepsy drug development

Where Sea Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sea Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Marketing channels4 records

Sea Pharmaceuticals product offering

Product offering

Core offering

Sea Pharmaceuticals is a private pre-clinical stage therapeutics R&D company developing proprietary synthetic small molecule drug candidates known as Dual AMPAR/KAINR Antagonists (DAKAs). Lead molecule SPM-0404 and second-generation SPM-0606 are being advanced through IND-enabling studies as potential oral treatments for constant bothersome tinnitus, epilepsy, and sporadic ALS. The molecules dampen excitatory glutamate neurotransmission in the CNS and demonstrate CNS penetration with acceptable pharmacokinetics in multiple species.

Product overview

Sea Pharmaceuticals is a private pre-clinical stage therapeutics R&D company developing a portfolio of proprietary synthetic small molecule neurotherapeutics targeting the glutamate pathway. The company's core pipeline consists of two drug candidates: lead molecule SPM-0404 and second-generation molecule SPM-0606, both functioning as dual AMPAR/KAINR antagonists (DAKAs). These oral CNS-penetrant compounds are being developed for high-need neurological disorders including tinnitus, epilepsy, and sporadic ALS. The company was founded in 2013 by J.P. Pearson and E.J. Martinez and operates from Cambridge, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPM-0404 Sea Pharmaceuticals' lead molecule SPM-0404 is a synthetic small molecule Dual AMPAR/KAINR Antagonist (DAKA) currently in IND-enabling studies. It is being developed as a potential oral treatment for constant bothersome tinnitus (CBT), epilepsy, and sporadic ALS (S-ALS). The molecule demonstrates potent and selective in vitro biological activity in whole cell patch-clamp electrophysiology recordings using rat neurons and human recombinant cells, and shows CNS penetration in rats and non-human primates with acceptable pharmacokinetics.
  • SPM-0606 A second-generation synthetic small molecule Dual AMPAR/KAINR Antagonist (DAKA) in Sea Pharmaceuticals' neurotherapeutic portfolio. SPM-0606 targets the glutamate neurotransmitter pathway for potential oral treatment of CNS disorders including tinnitus, epilepsy, and ALS, and is protected within Sea's 100% Sea-owned composition-of-matter patent estate.

Companies that use Sea Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Sea Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sea Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Inotiv, Inc. (NASDAQ:NOTV)coreStrategic or Co-development Partner · 6 April 2025Strategic relationship with Inotiv Inc. selected for pre-clinical development IND-enabling studies to support advancement of SPM-0404. Inotiv will perform development strategy, IND-enabling studies, and investigative studies. Dr. John E. Sagartz DVM PhD serves as Inotiv's Chief Strategy Officer and has collaborated with Dr. Pearson for over 20 years. Inotiv has contributed to development of many FDA-approved medicines worldwide and hundreds of IND molecules.
  • TCG GreenChem, Inc.coreStrategic or Co-development Partner · 14 November 2024Strategic collaboration with TCG GreenChem, Inc. of Ewing NJ USA for chemical development of lead molecule SPM-0404. TCG GC will conduct process optimization and analytical method development for cGMP manufacturing of SPM-0404 for IND-enabling studies and clinical trials. Chris H. Senanayake PhD (Founder, CEO & CSO) and Joe D. Armstrong III PhD (Chief Business Officer) are synthetic organic chemists with >500 IND molecules and several FDA-approved drugs in combined >65 years in pharma industry.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Sea Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: CNS-focused clinical-stage biopharmaceutical company developing novel neurotherapeutics for epilepsy and other CNS disorders. Directly comparable as a CNS small-molecule developer targeting underserved neurological indications with high unmet need.
  • Marinus Pharmaceuticals: Clinical-stage CNS company developing therapeutics for seizure disorders, including refractory epilepsies. Comparable target indications and small-molecule CNS strategy overlapping with Sea's epilepsy program.
  • Praxis Precision Medicines: Clinical-stage CNS company developing precision therapies for neurological disorders including epilepsy. Similar small-molecule approach and CNS pipeline profile make it a direct comparable.
  • Longboard Pharmaceuticals: Clinical-stage CNS company focused on novel treatments for neurological diseases. Comparable as a small-cap public CNS pharma targeting underserved neurological indications with small-molecule chemistry.
  • Xenon Pharmaceuticals: Clinical-stage CNS biopharma with a focus on epilepsy and other neurological disorders. Comparable small-molecule CNS development strategy and indication overlap with Sea's epilepsy program.
  • Tonix Pharmaceuticals: Clinical-stage CNS-focused biopharma developing small-molecule therapeutics across neurology and psychiatry indications. Comparable as a CNS small-molecule developer at similar pre-clinical/early clinical stage.

Emerging players

  • Otonomy: Clinical-stage biopharmaceutical company focused on otology, including tinnitus and hearing-related disorders. Directly comparable in the tinnitus indication where Sea is also competing.
  • Frequency Therapeutics: Clinical-stage company developing regenerative therapeutics for hearing loss with tinnitus-related indications. Comparable as an emerging player addressing the same otologic/neurology patient populations.

Broad incumbents

  • Acadia Pharmaceuticals: Commercial-stage CNS specialty pharma with a marketed neurology/neuropsychiatry portfolio. Relevant as a larger incumbent operating in Sea's CNS specialty space and a likely partner/acquirer profile.

Others

  • Inotiv: Public CRO providing pre-clinical drug development services including IND-enabling studies. Listed as a peer because Sea has selected Inotiv as its IND-enabling partner, making it both an operational collaborator and a relevant comparand for outsourced CNS pre-clinical development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Sea Pharmaceuticals social profiles

Digital presence

Sea Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sea Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Sea Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sea Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sea Pharmaceuticals

What does Sea Pharmaceuticals do?

Sea Pharmaceuticals is a private pre-clinical stage therapeutics R&D company developing proprietary synthetic small molecule drug candidates known as Dual AMPAR/KAINR Antagonists (DAKAs). Lead molecule SPM-0404 and second-generation SPM-0606 are being advanced through IND-enabling studies as potential oral treatments for constant bothersome tinnitus, epilepsy, and sporadic ALS. The molecules dampen excitatory glutamate neurotransmission in the CNS and demonstrate CNS penetration with acceptable pharmacokinetics in multiple species.

Is Sea Pharmaceuticals a public or private company?

Sea Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sea Pharmaceuticals founded?

Sea Pharmaceuticals was founded in 2013. It employs 1 to 10 people.

Where is Sea Pharmaceuticals based?

Sea Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

Who are Sea Pharmaceuticals's main competitors?

Direct peers on record are Sage Therapeutics, Marinus Pharmaceuticals, Praxis Precision Medicines, Longboard Pharmaceuticals, Xenon Pharmaceuticals and Tonix Pharmaceuticals. Emerging players are Otonomy and Frequency Therapeutics. Acadia Pharmaceuticals is listed as a broad incumbent. Inotiv is listed as an others.

Does Sea Pharmaceuticals have an API?

No public API is recorded for Sea Pharmaceuticals.

What industry is Sea Pharmaceuticals in?

Sea Pharmaceuticals's product category is Neurotherapeutics R&D. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals